Omar Tliba, PhD, has been appointed as a member of the editorial board of the American Journal of Respiratory Cell and Molecular Biology. Referred to in the field as the "red journal," the publication is issued by the American Thoracic Society to address the shift in modern pulmonary science to lung cell and molecular biology. Dr. Tliba is currently assistant professor in the department of pharmaceutical sciences at Jefferson School of Pharmacy (JSP).
"Membership on the editorial board of the red journal is a prestigious appointment and mark of distinction given by my colleagues in the field of pulmonary research," shares Dr. Tliba. "My duty is to uphold the scientific excellence required by the journal while being exposed to cutting edge science before it becomes available to anyone else. This invaluable opportunity will increase my visibility within the field and ultimately help me build an international reputation," he says
Dr. Tliba, in addition to teaching at JSP, conducts research on asthma, specifically the molecular mechanisms that mediate glucocorticoid resistance in chronic inflammatory diseases like asthma, Crohn’s disease and rheumatoid arthritis. His research findings inform the design of new therapeutic agents or alternatives to treat steroid resistance.
Dr. Tliba receives NIH funding for his research and was awarded biomedical research grants from the American Lung Association and Parker B. Francis family foundation. He is also an ad-hoc reviewer for different journals including Respiratory Research, European Respiratory Research, Journal of Allergy and Clinical Immunology, the American Journal of Physiology-Lung, Journal of Immunology, British Journal of Pharmacology, and the Journal of Biological Chemistry, and has lectured at professional symposia in the U.S., France, Australia and Canada.
For more information, contact Jane Clinton, 215-503-9865, email@example.com.